

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

**MEDICAL TECHNOLOGIES EVALUATION
PROGRAMME**

Equality impact assessment – Guidance development

**The Debrisoft monofilament debridement
pad for use in acute or chronic wounds**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

No equality issues were identified during the scoping process.
--

Inclusion as a special consideration was that although the device may have particular advantages for people with chronic wounds, the use of it will not exclude any groups of people.

- | |
|--|
| 2. Have any other potential equality issues been highlighted in the sponsor's submission, or patient organisation questionnaires, and, if so, how has the Committee addressed these? |
|--|

No equality issues were identified in the sponsor's submission or patient organisation questionnaires.
--

- | |
|---|
| 3. Have any other potential equality issues been identified by the Committee and, if so, how has the Committee addressed these? |
|---|

No equality issues were identified at the Committee meeting but it was noted that people with chronic wounds may be covered under the 2010 Equality

Act.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to or difficulties with access for the specific group?

Preliminary recommendations may allow the device to be more accessible to all groups of patients. There are no barriers or difficulties with access for any specific group.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

There is no potential for the preliminary recommendations to have an adverse impact on people with disabilities.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to , or difficulties with access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the Committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where?

There were no equality issues to consider.

Approved by Associate Director (name): Mark Campbell

Date: 11/11/2013

Medical technologies guidance document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No equality issues were identified during the consultation process.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

The recommendations were not changed after consultation. The final recommendations may allow the device to be more accessible to all groups of patients. There are no barriers or difficulties with access for any specific group.

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

5. Have the Committee's considerations of equality issues been described in the medical technologies guidance document, and, if so, where?

There were no equality issues to consider.

Approved by Programme Director (name): Mirella Marlow

Date: 18 March 2014